文献速递腹部CTMR

能谱CT与扩散加权成像定量预测局部进展期胃癌新辅助化疗病理缓解的对比

Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer.
PubMed 文献 · Eur Radiol · 2024-02-12

本研究基于前瞻性数据集的回顾性分析,纳入65例接受基线能谱CT三期增强与DWI-MRI检查、并接受标准新辅助化疗及根治性胃切除术的局部进展期胃癌患者,以肿瘤消退分级(TRG)为参考标准。延迟期标准化碘浓度(nICDP)与表观扩散系数(ADC)预测TRG分级的AUC分别为0.674与0.673,两者联合AUC升至0.770,且与无病生存相关(HR 2.508)。作者认为能谱CT与DWI预测效能相当,两者联合具有增量价值。

要点

  • 延迟期标准化碘浓度(nICDP)与ADC均与TRG相关,预测TRG分级的AUC分别为0.674与0.673。
  • nICDP与ADC联合后AUC升至0.770,较单一参数有显著提升。

核心结论

  • 能谱CT与DWI在预测局部进展期胃癌新辅助化疗病理缓解方面效能相当,nICDP与ADC联合具有显著增量获益并与无病生存相关。

研究设计与样本

  • 研究为取自前瞻性数据集的回顾性分析,纳入65例接受基线同期能谱CT三期增强与DWI-MRI检查、并接受标准新辅助化疗加根治性胃切除术的局部进展期胃癌患者,剔除图像质量差者。
  • 以肿瘤消退分级(TRG)为参考标准,将患者分为缓解组(TRG 0+1)与非缓解组(TRG 2+3)。
  • 在最大二维层面上手工放置自由手感兴趣区,测量碘浓度(IC)、标准化碘浓度(nIC)与表观扩散系数(ADC)。

关键影像表现/征象

  • 原文未报告具体的影像征象描述,定量参数为碘浓度(IC)、标准化碘浓度(nIC)与表观扩散系数(ADC)。

诊断标准与关键数值

  • 延迟期标准化碘浓度(nICDP)预测TRG分级的AUC为0.674,ADC预测TRG分级的AUC为0.673。
  • nICDP与ADC联合预测TRG分级的AUC为0.770,较单一参数显著提高(p;0.05,原文如此)。
  • nICDP与ADC均与TRG状态相关(采用Spearman相关系数检验)。

临床应用与阅片要点

  • 作者认为能谱CT与DWI是预测局部进展期胃癌新辅助化疗后病理消退结果的有效标志物,两者联合具有增量获益并与无病生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To compare the performance of spectral CT and diffusion-weighted imaging (DWI) for predicting pathologic response after neoadjuvant chemotherapy (NAC) in locally advanced gastric cancer (LAGC).

MATERIALS AND METHODS: This was a retrospective analysis drawn from a prospective dataset. Sixty-five patients who underwent baseline concurrent triple-phase enhanced spectral CT and DWI-MRI and standard NAC plus radical gastrectomy were enrolled, and those with poor images were excluded. The tumor regression grade (TRG) was the reference standard, and patients were classified as responders (TRG 0 + 1) or non-responders (TRG 2 + 3). Quantitative iodine concentration (IC), normalized IC (nIC), and apparent diffusion coefficient (ADC) were measured by placing a freehand region of interest manually on the maximal two-dimensional plane. Their differences between responders and non-responders were compared. The performances of significant parameters were evaluated by the receiver operating characteristic analysis. The correlations between parameters and TRG status were explored through Spearman correlation coefficient test. Kaplan-Meier survival analysis was adopted to analyze their relationship with patient survival.

RESULTS: nICDP and ADC were associated with the TRG and yielded comparable performances for predicting TRG categories, with area under the curve (AUC) of 0.674 and 0.673, respectively. Their combination achieved a significantly increased AUC of 0.770 (p ; 0.05) and was associated with patient disease-free survival, with hazard ratio of 2.508 (1.043-6.029).

CONCLUSION: Spectral CT and DWI were equally useful imaging techniques for predicting pathologic response to NAC in LAGC. The combination of nICDP and ADC gained significant incremental benefits and was related to patient disease-free survival.

CLINICAL RELEVANCE STATEMENT: Spectral CT and DWI-based quantitative measurements are effective markers for predicting the pathologic regression outcomes of locally advanced gastric cancer patients after neoadjuvant chemotherapy.

KEY POINTS: • The pathologic tumor regression grade, the standard criteria for treatment response after neoadjuvant chemotherapy in gastric cancer patients, is difficult to predict early. • The quantitative parameters of normalized iodine concentration at delay phase and apparent diffusion coefficients were correlated with pathologic response; their combination demonstrated incremental benefits and was associated with patient disease-free survival. • Spectral CT and DWI are equally useful imaging modalities for predicting tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li J, Xu S, Wang Y, et al. Spectral CT vs. diffusion-weighted imaging for the quantitative prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer. Eur Radiol. 2024. PMID: 38345605. doi:10.1007/s00330-024-10642-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。